MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.070
-0.060
-5.31%
Opening 13:21 01/28 EST
OPEN
1.130
PREV CLOSE
1.130
HIGH
1.182
LOW
1.050
VOLUME
444.80K
TURNOVER
--
52 WEEK HIGH
1.590
52 WEEK LOW
0.4000
MARKET CAP
30.96M
P/E (TTM)
-1.3757
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTXR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTXR News

  • Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses
  • Newsfile.1d ago
  • Citius Pharma Reports Outcome Of Interim Futility Analysis For Phase 3 Mino-Lok Pivotal Trial: 'Data Monitoring Committee recommends continuation of the trial with no changes'
  • Benzinga.12/19/2019 13:01
  • Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial
  • PR Newswire.12/19/2019 13:00
  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.12/06/2019 12:39

More

Industry

Pharmaceuticals
+0.41%
Pharmaceuticals & Medical Research
+0.58%

Hot Stocks

Name
Price
%Change

About CTXR

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
More

Webull offers Citius Pharmaceuticals Inc (CTXR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.